US FDA rejects closely watched lung cancer drug from China
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
This is a brief. The reporting belongs to The Straits Times — read the complete story, with full context and credits, at the source.
Read the full story at The Straits Times ↗straitstimes.com
How other newsrooms are covering it


More from the World desk
Just in

Moore on the chances of a 2028 presidential bid: ‘I’m still sorting it out’
Just in
Unwanted migrants are flooding Europe. Some are seizing on a divisive Australian solution
Just in

Europe will 'closely engage' in peace negotiations between Russia, Ukraine, von der Leyen says
Just in

China-US-Russia trilateral set for Thursday on Apec sidelines: Beijing
Just in

Leo XIV rides in a Peruvian military helicopter cockpit and reaches Cusco
Just in